• 핵의학기술
• /
• 제12권1호
• /
• pp.78-81
• /
• 2008

목적: 본 연구의 목적은 치료제를 복용하는 만성 B형간염환자의 혈청에서 seroconversion되는 과정 중에 불안정하게 나타나는 HBeAg과 HBeAb 사례를 연구하여, 검사자가 검사결과에 대한 정확한 이해를 하는데 도움을 주고자 하는 것이다. 방법: 만성 B형간염 환자로 진단을 받고 치료제를 복용하고 HBeAg 검사와 HBeAb검사를 시행한 3명을 대상으로 하였다. HBeAg과 HBeAb검사는 Radioimmunoassay법과 Immunoradiometric assay법으로 실시되었다. 결과: HBeAg이 음성화되는 과정에서 결과가 양성에서 음성으로, 다시 양성으로 불안정한 결과를 보였다. HBeAb가 양성화되는 과정에서 결과가 음성에서 양성으로, 다시 음성으로 변하는 불안정한 결과를 보였다. 결론: 이번 사례는 seroconversion 유도를 위해 약물치료중인 만성 B형간염 환자에서 볼 수 있는 불안정한 HBeAg과 HBeAb 혈액 결과이다. 불안정한 HBeAg과 HBeAb 검사 결과를 통하여 검사자는 환자가 바이러스 치료제를 복용하여 seroconversion되는 과정 중에 있을 수 있다는 것과 불안정한 결과는 치료제에 의해 일어나는 자연스러운 현상임을 알 수 있다.

• 대한임상검사과학회지
• /
• 제43권2호
• /
• pp.57-67
• /
• 2011

In this study, we investigated the correlation between the administration of various antiviral agents and the alternation of specific biomarkers induced by the hepatitis B virus (HBV). Eligible subjects diagnosed with chronic hepatitis B were prescribed with antiviral drugs at the Gastroenterology Internal Medicine Department of E University Hospital in Daejeon between May 2004 and September 2009. Lamivudine was prescribed to 66 out of 100 patients. Of the 12 patients, 6 (50.0%) showed a change from being HBe-antigen-positive to being HBe-antigen-negative. Of the 39 patients, 23 (59.0%) showed higher than 40 IU/L alanine aminotransferase (ALT). Of the 65 patients, 41 (63.1%) showed HBV DNA decrease of 1 log, and were prescribed with Lamivudine. Adefovir was prescribed to 3 out of 100 patients. Of the 12 patients, 1 (8.3%) showed a change from being HBe-antigen-positive to being HBe-antigen-negative, and was prescribed with Adefovir. Entecavir was prescribed to 19 (19.0%) out of 100 patients. Of the 12 patients, 3 (25.0%) showed a change from being HBe-antigen-positive to being HBe-antigen-negative. Of the 12 patients, 3 (125.8%) showed higher than 40 IU/L ALT. Of the 65 patients, 14 (21.5%) showed HBV DNA decrease of 1 log, and were prescribed with Entecavir. Clavudine was prescribed to 7 out of 100 patients. Of the 12 patients, 1 (8.3%) showed a change from positive HBe antigen to negative HBe antigen. Of the 39 patients, 5 (12.8%) showed higher than 40 IU/L ALT. Of the 65 patients, 6 (9.2%) showed HBV decrease of 1 log, and were prescribed with Clavudine. These results do not show a statistically significant correlation between drugs and biomarkers. Data on combination therapy using Lamivudine and Adefovir show no statistically significant difference between drugs and biomarkers. Medications for periodic inspection was not correlated to HBe-antigen-negative conversion, ALT, and HBV DNA. HBV DNA was significantly reduced in patients with high levels of AST(aspartic acid aminotransferase) and ALT before treatment. In addition, the decrease of HBV DNA after 12 months of treatment was less frequently observed in patients treated with Lamivudine compared with other drugs. This result is associated with Lamivudine resistance. Although the association of drugs with diagnostic markers and the correct choice of treatment is difficult to determine, these results may be useful for further research on diagnosis and treatment of the hepatitis B virus.

• Clinical and Experimental Pediatrics
• /
• 제45권6호
• /
• pp.727-731
• /
• 2002

목 적 : HBsAg 양성이면서 HBeAg 양성인 산모에서 태어난 신생아에서 출생 직후 HBsAg은 음성이면서 HBeAg 양성이 어떤 의미가 있는 것인지에 대해 알아보았다. 방 법: 1996년 12월부터 1999년 3월까지 HBsAg과 HBeAg이 모두 양성인 산모로부터 출생한 신생아 중에서 HBsAg 음성이면서 HBeAg 양성인 신생아 22명을 대상으로 추적 관찰하였다. 결 과 : 1) 분만 산모의 총 수 4,338명 중 HBsAg 양성은 4.9%(213/4338), HBsAg 양성인 산모에서 HBeAg을 검사한 183례 중 HBeAg 양성은 41.5%(76/183)이었다. 2) HBeAg 양성인 산모에서 출생한 신생아에서 HBeAg 검사를 시행 받은 49례에서 HBsAg 음성이고 HBeAg 양성인 신생아는 36례로 73.5%이었다. 이중 추적관찰이 가능했던 22례에서 태반을 통해 전달된 HBeAg이 2개월 내에 소실된 경우가 7례(31.3%)로 가장 많았으며 90%이상이 12개월 내에 소실되었으며 결국 22례 모두에서 소실되는 소견을 보였다. 단 1례에서 HBeAg은 소실되었으나 6개월에 HBsAg이 양성이었다. 결 론: HBeAg이 양성인 간염 보균산모에서 신생아의 HBeAg은 감염이라기 보다는 태반을 통해 전달되는 산모의 HBeAg으로 일시적인 현상이며 임상적인 문제없이 소실되는 것으로 사료된다.

• Journal of Microbiology and Biotechnology
• /
• 제18권10호
• /
• pp.1722-1728
• /
• 2008

The natural course of chronic hepatitis B (CH-B) virus infection is reportedly variable, and the long-term outcomes in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B infection are distinct from HBeAg-positive chronic hepatitis. However, the molecular virological factors that contribute to the progression of liver disease in the south Indian setting remain largely unclear. We prospectively studied 679 consecutive patients for HBsAg, HBeAg, anti-HBe, and HBV DNA by qualitative PCR. Randomly selected samples were subjected to bidirectional sequencing to reveal core/precore variants. Of the total 679 chronic HBV cases investigated, 23% (154/679) were replicative HBV carriers. Furthermore, amongst the 560 HBV DNA samples analyzed, 26% (146/560) were viremic. Among the 154 HBeAg positive cases, HBV DNA was positive in 118 cases (77%), significantly (p<0.001) higher than the anti-HBe positive (7%) (28/406) cases. Significant increase in liver disease (p<0.01) with ALT enzyme elevation (p<0.001) was observed in both HBe and anti-HBe viremic cases. Interestingly, low frequencies of mutations were seen in the precore region of the HBV strains studied. HBV precore and core promoter variants were less often detected in subjects with "e" negative chronic HBV infection and, therefore, may not have a prognostic role in determining liver disease sequelae in this part of tropical India.

• 미생물학회지
• /
• 제29권2호
• /
• pp.80-84
• /
• 1991

We cloned and expressed hepatitis B viral core antigen (HBcAg) gene in E. coli using $P_{L}$ promoter system. For optimal expression of the gene, we undertook the studies on the effects of the distance between Shine-Dalgarno (SD) sequence and start codon, copy number of repressor gene, induction temperature, and the stability of the core antigen. The results demonstrated that the induction at 37.deg.C was more efficient than at 42.deg.C, and the 11 base pairs (bp) distance between SD sequence and start codon of HBcAg gene was more efficient than the 15 bp distance in E. coli. The copy number of cI857 repressor gene did not influence on the expression of HBcAg, and the expression level of HBcAg in mutant type (low protease activity) and wild type strains was almost the same. The produced core antigen appeared to be HBcAg not HBeAg judged by two different radioimmunoassat (RIA) kits. This result suggested that the antigen was stable in E. coli.i.

• 한국약용작물학회:학술대회논문집
• /
• 한국약용작물학회 2009년도 심포지엄 및 춘계학술발표회
• /
• pp.239-240
• /
• 2009

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권11호
• /
• pp.5463-5467
• /
• 2012

Hepatitis B virus (HBV) infection is contagious with transmissiobn vertically or horizontally by blood products and body secretions. Over 50% of Iranian carriers contracted the infection prenatally, making this the most likely route of transmission of HBV in Iran. To evaluate the resistance to adefovir (ADV) therapy in patients with chronic hepatitis B infection, a study was conducted on 70 patients (63 males and 7 females), who had received in first line lamivudine and second line adefovir. All were tested for the presence of hepatitis B surface antigen (HBsAg), hepatitis B envelope antigen (HBeAg), serum alanine amino transferase (ALT) level and HBV DNA load before and after treatment with ADV. In all samples, resistance to lamivudine and ADV was tested with real time PCR. Among seventy patients with chronic hepatitis B infection, 18 (25.7%) were resistant to LAM and 8 (11.4%) were resistant to ADV. Only one patient was negative for the presence of HBS-Ag (5.6%) and two were negative for HBe-Ag (11.1%). In this study we used a new method (ALLGIO probe assay) that has high sensitivity in detection of adefovir resistance mutants, which we recommend to other researchers. Mutant strains of the YMDD motif of HBV polymerase can be found in some patients under treatment with lamivudine and ADV. ADV has been demonstrated to be efficient in patients with lamivudine resistant HBV.

• 대한의생명과학회지
• /
• 제29권4호
• /
• pp.314-320
• /
• 2023

The purpose of this study was to provide basic data on hepatitis B infection control in the community through the results of the hepatitis B surface antigen and antibody tests conducted at the Cheongyang-County Health Medical Center. From 2012 to 2020, we retrospectively analyzed the HBsAg, HBsAb, HBeAg, HBeAb, and HBV DNA results of 7,329 hepatitis B-related testers. Among 7,329 subjects, the HBsAg positivity rate was 1.7%, and the positivity rate according to age was the highest at 4.4% in their 30s, 4.2% in their 40s, 4.1% in their 50s, 2.0% in their 60s, 1.9% in their 70s and over, and 10 it was shown in the order of 0.3% from less than large. The HBsAb positivity rate was 43.1% for men, 38.2% for men, and 46.7% for women (P<0.001). To summarize the above results, for infection control of hepatitis B in Cheongyang-County, hepatitis surface antigen proton management is required for those in their 30s or older, and it is thought that efforts to acquire immunity are necessary for those in their 20s or younger.

• 미생물학회지
• /
• 제27권3호
• /
• pp.169-175
• /
• 1989

포유동물 세포내에서 간염 바이러스의 내면항원의 발현과 전위내면 항원(precore) 부위의 역할을 규명하기 위하여 고등동물세포 발현용 벡터에 전위내면항원 부위를 갖거나 또는 갖지 않는 내면항원 유전자를 클로닝 하여 COS 세포내에서의 발현을 조사하였다. 전위내면항원 부위를 포함한 내면항원 유전자를 갖는 플라스미드로감염시킨 COS 세포는 항원들이 세포추출물과 배양액에서 검출되었다. 분비된 항원의 증가율은 감염후 2일과 3일 사이가 가장 높았고, 부분결실된 제조합 플라스미드 중 내면항원의 ATG codon에서 180bp 떨어진 것이 가장 발현이 잘 되었다. 전위내면항원을 갖지 않거나 하나의 염기가 첨가되어 변형된 전위내면항원을 갖는 제조합 플라스미드의 경우 항원들이 세포 추출물에서만 검출되었다. 이러한 사실은 전이내면항원 부위가 HBe 항원의 분비에 관여 한다는 경우 항원들이 세포 그러나 대장균이나 효모 세포의 경우는 전위내면항원의 존재와 상관없이 항상 세포추출물에서만 존재하는 것으로 보아 이들 세포의 경우에서는 전위내면항원 부위가 HBe 항원의 분비에 영향을 줄 수 없음을 의미한다.

• 미생물학회지
• /
• 제28권1호
• /
• pp.1-5
• /
• 1990

B형 간염바이러스($\alpha$dr 형)의 내면항원(HBcAg) 유전자는 두개의 단백질 합성시작 유전자 암호 ATG를 갖는다. 하나는 전위내 면항원을 다른 하나는 내면항원 유전자들 위한 ATG 부호이다. 내연항원의 발현과 전위내면항원의 역할을 연구한기 위하여 전위내면 항왼 유전자를 포함하는 것과 포함하지 않는 내연항원 유전자를 효모발현 운반체에 클j료녕 하였다. 또한 내면항원의 발현에 5 upstream 의 역할을 알아보기 위하여 여러 가지의 5’ 제거툴연변이체를 클로닝하였다. 앞에서 만들어진 플라스미드로 여러 효모 균주을 형질전환시킨 후 발헨된 내면항원과 그와 관련된 항원 HBeAg을 방사면역측정법 으로 확인하였다. 효모에서 내면항원 발현의 최적조건 허에서 가장 높은 수준의 항원은 PGK promoter 와 terminator에 내연향원 올 포함한 pGKHBc를 가진 SHY4에서 검출되었다. 전위내면부위의 존재와 우관하게 내면항원은 배양액에서는 검출되지 않고 세포내에서만 검출되었다. 이 결과는 전위내면항원이 효모 내에서 내연항왼의 분비에 영향올 주지않음을 의미한다.